The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide

Future prospective studies, adverse event reporting and post-marketing surveillance will certainly contribute to establishing if LCV represents a less rare than expected side effect of both oral and subcutaneous semaglutide formulations.